Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Viridian Therapeutics

Explore full profile

Focused on the development therapeutics for the treatment of cardiovascular and muscle diseases

Boulder, United StatesFounded 2007Biotech & Life Sciences
Valuation $1.44B Market cap · 2026
Revenue $71M Latest reported FY
Total funding $100–500M Disclosed equity funding

About Viridian Therapeutics

Viridian Therapeutics is a biopharmaceutical company that discovers and develops microRNA (miRNA)-targeting therapies. The company is focused on developing innovative therapies for thyroid eye disease through advanced monoclonal antibody technology targeting the IGF-1R pathway.

Read full description

Viridian Therapeutics operates in the biopharmaceutical market, specifically focusing on rare autoimmune diseases. Its clients are patients suffering from these conditions. The company's business model revolves around the discovery, development, and subsequent commercialization of novel treatments. As a clinical-stage biopharmaceutical company, its revenue generation will likely depend on the successful approval and market launch of its therapeutic candidates.

Source: Dealroom company data

At a glance

Founded
2007
Headquarters
Boulder, United States
Listing
IPO 2017
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tierThoroughbred$100M+ revenue

Knowledge graph

News, research, reports and resources connected to this company by Dealroom
News Viridian Therapeutics raises $350M in upsized dual public offerings Jun 3, 2026

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Boulder Ventures
  • Atlas Venture
  • Broadview Ventures
  • Amgen Ventures
  • Remeditex Ventures

Series B and later8 investors entered at this stage

  • MP Healthcare Venture Management
  • JAFCO
  • Brace Pharma
  • MRL Ventures
  • Fidelity Investments
  • Hercules Capital
  • Braidwell
  • DRI Healthcare

Talent

Book a demo to see the people
Employees mapped 278 incl. 1 AI specialist
Founders Hidden — book a demo/100 quality score
Key operators 18 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
6 countries with
team presence
🇺🇸 United States98.2%
🇫🇷 France0.3%
🇦🇹 Austria0.3%
🇰🇼 Kuwait0.3%
🇬🇧 United Kingdom0.3%
Top 5 of 6 shown
Web traffic by country
17K monthly visits
across markets
🇺🇸 United States47.6%
🇨🇦 Canada25.3%
🇮🇳 India10.6%
🇬🇧 United Kingdom5.9%
🇵🇭 Philippines2.9%
Top 5 markets shown

Patents

Estimated portfolio value
$59M

32 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Viridian Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Viridian Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles